Palisade Bio (PALI) AI Stock Analysis

• Market Cap: $260.76M
• Dividend Yield: N/A
• Average Volume (3M): 4.53M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.08
• Revenue Growth: N/A
• EPS Growth: 71.95%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 149,003,200
• 10 Day Avg. Volume: 4,196,076
• 30 Day Avg. Volume: 4,525,639
• PEG Ratio: <0.01
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.19
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.81K
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $13.00
• Price Target Upside: 642.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $2.00 ▲(14.29% Upside)

The score is held back primarily by weak fundamentals (no revenue, ongoing losses, and sizable cash burn), partially offset by strong technical momentum (price above major moving averages with positive MACD). Valuation support is limited due to a negative P/E and no dividend, while recent corporate events are mixed (Nasdaq compliance regained but governance-related negatives).

Positive Factors

Innovative Product Pipeline

Palisade Bio's development of PALI-2108 highlights its innovative approach in addressing unmet needs in gastrointestinal health, potentially strengthening its market position and driving future growth.

Strategic Partnerships

Strategic partnerships provide Palisade Bio with funding and shared resources, enhancing its ability to bring products to market and potentially improving long-term revenue prospects.

Low Leverage

A low debt-to-equity ratio indicates financial stability and flexibility, allowing Palisade Bio to navigate financial challenges and invest in growth opportunities without excessive debt burden.

Negative Factors

Consistent Losses

Persistent financial losses and negative cash flow highlight operational challenges, potentially limiting the company's ability to sustain long-term growth and invest in R&D without external funding.

Reliance on External Financing

Dependence on external financing poses sustainability risks, as it may become challenging to secure funding in the future, impacting the company's ability to continue operations and development.

No Revenue Growth

Lack of revenue growth indicates challenges in product commercialization and market penetration, which could hinder the company's ability to achieve profitability and financial independence.

Palisade Bio Business Overview & Revenue Model

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

How the Company Makes Money

Palisade Bio makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its therapeutics to market, either independently or through strategic partnerships with larger pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, or milestone payments, which provide Palisade Bio with funding and shared resources. The company's revenue streams are heavily reliant on successful clinical trials, regulatory approvals, and the ability to effectively market its products to healthcare providers and patients. Additionally, Palisade Bio may secure funding through grants or investments to support its research and development efforts.

Palisade Bio Financial Statement Overview

Summary

Overall, Palisade Bio is struggling financially with consistent losses and negative cash flow. The balance sheet shows some stability due to low leverage, but the lack of revenue growth and profitability are significant concerns. The company heavily relies on external financing, which may not be sustainable long-term.

Income Statement

Palisade Bio shows no revenue growth and has been operating at a loss consistently. The gross profit margin is null due to no revenues, and the company faces a significant negative net profit margin, indicating poor profitability. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company has maintained a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the equity ratio has been fluctuating, with a recent decline in stockholders' equity. Despite this, Palisade Bio maintains more equity than debt, providing some stability.

Cash Flow

Palisade Bio's cash flow situation is concerning with negative free cash flow and operating cash flow. The company has been relying on financing activities to cover its negative cash flows, which poses sustainability risks. The free cash flow to net income ratio is negative, indicating cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	250.00K	0.00	0.00	0.00
Gross Profit	-1.00K	0.00	250.00K	0.00	0.00	-146.00K
EBITDA	-11.25M	-14.42M	-12.28M	-14.24M	-24.22M	-9.94M
Net Income	-11.23M	-14.44M	-12.30M	-14.26M	-26.62M	-10.32M
Balance Sheet
Total Assets	6.97M	10.88M	14.05M	15.76M	12.51M	3.02M
Cash, Cash Equivalents and Short-Term Investments	5.23M	9.82M	12.43M	12.38M	10.49M	729.00K
Total Debt	211.00K	169.00K	369.00K	404.00K	199.00K	1.42M
Total Liabilities	3.76M	3.39M	2.74M	3.28M	5.15M	10.12M
Stockholders Equity	3.21M	7.49M	11.31M	12.48M	7.37M	-7.10M
Cash Flow
Free Cash Flow	-10.08M	-12.19M	-11.14M	-13.37M	-14.77M	-4.77M
Operating Cash Flow	-10.08M	-12.19M	-11.13M	-13.36M	-14.77M	-4.77M
Investing Cash Flow	0.00	0.00	-4.00K	-10.00K	-54.00K	-6.00K
Financing Cash Flow	7.27M	9.58M	11.19M	15.26M	24.61M	1.89M

Palisade Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Neutral. The current price of 1.75 is below the 20-day moving average (MA) of 2.04, below the 50-day MA of 1.99, and above the 200-day MA of 1.19, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 10.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PALI.

Palisade Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PALI	53 Neutral	$260.76M	-0.39	-228.64%	―	―	71.95%
OBIO	52 Neutral	$235.46M	-2.32	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBP	49 Neutral	$143.41M	-1.51	-55.65%	―	―	-17.43%
PYXS	47 Neutral	$114.57M	-1.11	-87.28%	―	-82.53%	-52.00%
ELDN	44 Neutral	$155.43M	-1.76	-95.49%	―	―	72.35%

Palisade Bio Corporate Events

Palisade Bio Approves Key Proposals at Stockholder Meeting

On December 3, 2025, Palisade Bio held a special meeting of stockholders where key proposals were approved. The stockholders approved the issuance of up to 8,637,810 shares of common stock underlying certain warrants, an amendment to increase the number of authorized shares of common stock from 280,000,000 to 300,000,000, and a proposal to adjourn the meeting if necessary to solicit additional proxies.

The most recent analyst rating on (PALI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.

Palisade Bio Terminates Phantom Unit Plan

On September 4, 2025, Palisade Bio, Inc. approved a Phantom Unit Plan to grant compensatory awards to certain employees, directors, and consultants. However, on October 22, 2025, the company decided to terminate the plan, resulting in the cancellation of unvested Phantom Units for key executives without any compensation.

The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.

Palisade Bio Approves Reverse Stock Split Amendment

On October 17, 2025, Palisade Bio, Inc. held its annual meeting of stockholders. During the meeting, three directors were elected, Baker Tilly US, LLP was ratified as the independent registered public accounting firm, and an amendment for a reverse stock split was approved. The reverse stock split, to be executed at a ratio between 1-for-5 and 1-for-50, is set to occur by December 31, 2025, at the board’s discretion.

The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.